Black phosphorus assisted polyionic micelles with efficient PTX loading for remotely controlled release and synergistic treatment of drug-resistant tumors

Abstract

Nanomedicines have been widely used in the effective delivery of chemotherapeutic drugs due to their advantages such as increasing the half-life of drugs, selectively targeting tumor tissues, and thus reducing...

Recent advances in the targeted delivery of paclitaxel nanomedicine for cancer therapy

“…64 PTX is an effective chemotherapy drug and has been a part of numerous nanoformulations, which have several advantages over conventional therapy. 65 Firstly, the water solubility of PTX can be greatly improved when it is conjugated with hydrophilic polymers or when encapsulated in liposomes. Secondly, due to their smaller particle size, the delivery of PTX is targeted to the tumor due to the increased permeability and retention effect (EPR).…”

Progress of Nanomaterials-Based Photothermal Therapy for Oral Squamous Cell Carcinoma

“…The particle size of PD-M@BP/PTX was 124–162 nm, with an encapsulation efficiency of more than 94% and excellent colloidal stability. In vivo, PD-M@BP/PTX not only significantly inhibited the proliferation of tumors, but also reduced the potential damage of chemotherapy drugs to the whole body [ 139 ].…”

Dually crosslinked degradable polyionic micelles for sustained glucose-responsive insulin release

“…Polyanionic micelles that load protein drugs can significantly increase drug loading, reduce immune response and improve circulatory stability in vivo, thereby enhancing therapeutic efficacy at the site of pathogenesis. [32][33][34][35] In particular, the first crosslinking structure ( phenylboronic acid ester, singly crosslinked micelles (SCM@insulin)) was formed via the interaction between o-glycol-modified poly(ethylene glycol)-poly(dimethylamino carbonate)-poly(dimethylamino-trimethylene carbonate) (mPEG-PAC-PDMATC) and phenylboronic acid-introduced mPEG-PAC-PDMATC (mPEG-P(AC-co-MPD)-PDMAC and mPEG-P(AC-co-MAPBA)-PDMATC, respectively), followed by the formation of the second crosslinked structure after UV exposure (UV-crosslinked structure, dually crosslinked micelles (DCM@insulin)). The UV-crosslinked structure protected the loaded insulin against protease degradation and enhanced the stability under multiple insulin releases, and the phenylboronic acid ester structure endowed DCM@insulin with the capability to release in a glucose-responsive manner, leading to enhanced the glycemic control and improved glucose utilization (Scheme 1).…”